This study researches the market size of Human Coagulation Factor VIII, presents the global Human Coagulation Factor VIII sales and revenue by companies, regions, type and application, history breakdown data from 2013 to 2018, and forecast to 2025.This report focuses on the key data information of Human Coagulation Factor VIII in key regions like North America, Europe, Asia Pacific, Central & South America, and Middle East & Africa, presents sales, revenue, market share, growth rate of Human Coagulation Factor VIII for each region and countries in each region.
For top companies, this report investigates and analyzes the sales, revenue, market share and growth rate for the top players, key data from 2013 to 2018.
This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter’s Five Forces Analysis.
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A.
North America is the largest consumption market of Human Coagulation Factor VIII, with sales market share nearly 46%. And the production market share of Human Coagulation Factor VIII is 58%. The manufacturers of Human Coagulation Factor VIII in North America have big and medium scale.
The second place is Europe, following North America with the sales market share of 36% and the production market share over 28%. Many European players have plants in USA due to rich plasma source. So there are a large number of Human Coagulation Factor VIIIs for import from other regions.
Asia is another important market of Human Coagulation Factor VIII, enjoying 10% production market share and 11% sales market share. Especially in China, the sales and price of Factor VIII are controlled by country, and the price in China is different from other regions.
Main players are from USA and Europe, like Baxter, Bayer, and they have many plants in other regions. China also can supply Human Coagulation Factor VIII, but the products are mainly consumed in China.
Market competition is intense. Baxter, Bayer, CSL, Pfizer, Grifols, etc. are the leaders of the industry, and hold key technologies, with high-end customers, have been formed in the monopoly position in the industry. However, with further expanding market, there will be more manufactures in the future.
In 2018, the global Human Coagulation Factor VIII market size was 7440 million US$ and is forecast to 9420 million US in 2025, growing at a CAGR of 3.0% from 2018. In this study, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Human Coagulation Factor VIII.
Request to Buy Full Report@
This report includes the following manufacturers; we can also add the other companies as you want.
Market Segment by Product Type
Recombinant Factor VIII
Plasma-derived Factor VIII
Market Segment by Application
Spontanous / Trauma
Market size split by Region
Central & South America
Rest of Central & South America
Middle East & Africa
Ask for Discount on Research Report and Request Sample Copy of Report@
About QY Research
QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert’s resources (included energy automotive chemical medical ICT consumer goods etc.
If you are interested in it or have any questions,please contact me.
QYResearch Inc. | More Than 120,000 Market Research Reports
Global Market Research Report Leading Publisher
QY Research, INC.
US Phone: 00-1-626-295-2442
Address: 17890 Castleton Street Suite 218 City of Industry CA 91748 United States